• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

Medicines Company gets a boost as ‘Cangrelor looks approvable’

April 14, 2015
By Marie Powers
FDA briefing documents posted ahead of Wednesday’s meeting of the Cardiovascular and Renal Drugs Advisory Committee (adcom) meeting to review the approvability of cangrelor were sufficiently positive to give shares of The Medicines Co. (NASDAQ:MDCO) a modest boost Monday.
Read More

Abeona advances rare disease drugs via nontraditional route

April 13, 2015
By Marie Powers
Partnering with patient advocacy organizations is an increasingly attractive avenue to speed drugs for rare indications into clinical development. For the smallest of biotechs, the strategy also can keep a company afloat.
Read More

Over the 'Edge' series C provides $72.5M for brain bleed drug

April 10, 2015
By Marie Powers
Lead candidate EG-1962, a polymer-based microparticle formulation of the FDA-approved calcium channel inhibitor nimodipine, more than piqued the curiosity of investors, who plowed approximately $72.5 million into Edge Therapeutics Inc. in two follow-on C rounds.
Read More

Mylan makes its move on Perrigo; is Teva the elephant in the room?

April 9, 2015
By Marie Powers
Mylan NV disclosed Wednesday that it issued what it called "a preliminary proposal" to acquire Perrigo Co. plc for $205 per share, paid in an undisclosed combination of cash and Mylan stock, to create a global powerhouse across branded, generic and over-the-counter (OTC) pharmaceuticals.
Read More

Adaptimmune 'Ts' up $150M IPO, Nasdaq listing

April 8, 2015
By Marie Powers
One of the hottest companies in the sizzling cancer immunotherapy space, Adaptimmune Ltd., filed its F-1 with the SEC, seeking a $150 million IPO and a Nasdaq listing for its American depositary shares under the ticker ADAP.
Read More

Curiosity steers Rienhoff along 'crooked' path of personal, professional discovery

April 6, 2015
By Marie Powers
"If the truth were known, mothers would really not want their children to be entrepreneurs," observed Hugh Young Rienhoff Jr., surmising that such a path – which he called part decision, part fate – suggested difficulties conforming to the corporate or academic worlds.
Read More

Heron Therapeutics hopes its third NDA filing will be 'MAGIC' for Sustol

April 3, 2015
By Marie Powers
Having resolved issues with its manufacturing supply chain and conducted an additional phase III study over and beyond requirements set by the FDA in two previous complete response letters (CRLs), Heron Therapeutics Inc. is confident the finish line is in sight for lead product Sustol (granisetron injection) to prevent delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of moderately or highly emetogenic chemotherapy (MEC/HEC) agents.
Read More

'Eye' see: Kala Pharma's nanoparticle-formulated drug hits in phase III

April 2, 2015
By Marie Powers
KPI-121, Kala Pharmaceuticals Inc.'s topical nanoparticle formulation of loteprednol etabonate (Lotemax, Bausch & Lomb), emerged with flying colors from a phase III study evaluating the lead program for the treatment of inflammation and pain following cataract surgery.
Read More

Horizon raises its rare disease profile with $1.1B Hyperion buy

March 31, 2015
By Marie Powers
Horizon Pharma plc is looking to add approved drugs Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate) to its orphan drug business by acquiring the outstanding shares of developer Hyperion Therapeutics Inc. for $46 apiece in cash, or approximately $1.1 billion.
Read More

Kura Oncology rewinds interesting drug 'developed in the wrong era'

March 30, 2015
By Marie Powers
Kura Oncology Inc. made a big splash in the even bigger oncology drug development pond this month.
Read More
Previous 1 2 … 84 85 86 87 88 89 90 91 92 … 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Deal handshake with coin, chart background

    After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

    BioWorld
    Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe